Navigation Links
Commercialization aim of grant supporting technology that destroys cancer cells
Date:8/13/2008

Blacksburg, Va. -- A new technology, using electric pulses to destroy cancer tissue and named by NASA Tech Briefs as one of seven key technological breakthroughs of 2007, is receiving additional support aimed at moving the procedure to the marketplace. One of its lead developers, Rafael V. Davalos, a faculty member of the Virginia TechWake Forest University School of Biomedical Engineering and Sciences (SBES), received a $240,000 grant from the Wallace H. Coulter Foundation and $25,000 from the Wake Forest Comprehensive Cancer Center.

Davalos' grant from Coulter is an Early Career Translational Research Award in Biomedical Engineering. This early career awards program provides funding for assistant professors in established biomedical engineering departments within North America. The award seeks to support biomedical research that Coulter considers promising with the goal of progressing toward commercial development.

The technology, irreversible electroporation (IRE), was invented by Davalos and Boris Rubinsky, a bioengineering professor at the University of California, Berkeley.

Electroporation is a phenomenon that increases the permeability of a cell from none to a reversible opening to an irreversible opening. With the latter, the cell will die. For decades, biologists have used reversible electroporation in laboratories to introduce drugs and genes into cells while trying to avoid irreversible electroporation. By contrast, biomedical engineers Davalos and Rubinsky are now using irreversible electroporation to target cancer cells in the body.

IRE would be a minimally invasive surgical focal-ablation technique that could remove the undesirable tissue without the use of heat such as radiation. The IRE procedure involves placing small needles near the targeted region. The needles deliver a series of low energy microsecond electric pulses to the targeted tissue and the area treated can be monitored in real time using ultrasound. In laboratory testing, IRE destroyed targeted tissue with sub-millimeter resolution, and it proved easy to control and to be precise.

Furthermore, "the procedure spares nerves and major blood vessels, enabling treatment in otherwise inoperable areas," added Davalos, the 2006 recipient of the Hispanic Engineer National Achievement Award for Most Promising Engineer.

Davalos and his colleagues published the first experiments on using IRE on tumors in the November 2007 issue of PLoS ONE. Their optimal parameters achieved complete regression in 92 percent of the treated tumors in vivo in preclinical mouse models. These results were achieved with a single treatment that lasted less than five minutes. Collaborator Lluis M. Mir, director of the Laboratory of Vectorology and Gene Transfer research of the Institut Gustave Rousssy, the leading cancer research center in Europe, and one of the Centre National de la Recherche Scientifique (CNRS), led the study.

In April 2008, Gary Onik, a radiologist with Florida Hospital (www.hopeforprostatecancer.com/) and Rubinsky conducted a pilot study on five people on soft tissue in the prostate to prove the safety of the procedure on humans.


'/>"/>

Contact: Lynn Nystrom
tansy@vt.edu
540-231-4371
Virginia Tech
Source:Eurekalert

Related biology news :

1. UTMB inventions win University of Texas System commercialization awards
2. IEEE Homeland Security Conference Business Panel to feature experts on technology commercialization
3. UCs NIH grant brings technology from outer space to playgrounds
4. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
5. Homeland Security awards 2 grants to Rutgers for nuclear threat detection
6. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
7. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
8. Genes and environment grant funds close look at nature-nurture overlap in common diseases
9. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
10. NIH awards UC $9 million grant to improve patient point-of-care technologies
11. UAB wins $5.7M neurofibromatosis grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: